Inhibition of the PI3K-Akt-mTOR pathway may be a promising therapeutic option for approximately 70% of breast cancer patients with bone metastasis.303 The ability of these agents to effectively cross the BBB remains a significant challenge. Here, AKT1 is linked to breast carcinoma.